We are live on
!
Find out more
PBM
Propel Bio Management Portfolio holdings
AUM
$191M
1-Year Est. Return
102.42%
This Fund
S&P 500
This Quarter
Est. Return
-15.48%
1 Year Est. Return
+102.42%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$101M
AUM Growth
-$71.7M
(-42%)
Cap. Flow
+$15.8M
Cap. Flow
% of AUM
15.68%
Top 10 Holdings %
Top 10 Hldgs %
90.34%
Holding
23
New
2
Increased
4
Reduced
2
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
APLT
Applied Therapeutics
APLT
|
+$19.1M |
| 2 |
Phathom Pharmaceuticals
PHAT
|
+$1.49M |
| 3 |
Syndax Pharmaceuticals
SNDX
|
+$856K |
| 4 |
Jasper Therapeutics
JSPR
|
+$416K |
| 5 |
Delcath Systems
DCTH
|
+$179K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Telesat
TSAT
|
+$4.82M |
| 2 |
Ardelyx
ARDX
|
+$663K |
| 3 |
Verrica Pharmaceuticals
VRCA
|
+$500K |
| 4 |
CMPS
Compass Pathways
CMPS
|
+$278K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 76.74% |
| 2 | Energy | 23.23% |
| 3 | Miscellaneous | 0.03% |
| 4 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Plains GP Holdings
PAGP
$5.52B
| $23.4M | 23.23% |
1,272,360
| – | – |
|
2
Madrigal Pharmaceuticals
MDGL
$12.5B
| $13.3M | 13.19% |
43,032
| – | – |
|
|
AKRO
3
DELISTED
Akero Therapeutics
AKRO
| $9.56M | 9.5% |
343,729
| – | – |
|
4
Achieve Life Sciences
ACHV
$874M
| $8.63M | 8.58% |
2,453,092
| – | – |
|
|
APLT
5
DELISTED
Applied Therapeutics
APLT
| $8.23M | 8.18% |
9,615,420
+3,047,562
| +46% | +$19.1M |
|
|
6
Phathom Pharmaceuticals
PHAT
$769M
| $8.04M | 7.98% |
989,927
+120,000
| +14% | +$1.49M |
|
7
TScan Therapeutics
TCRX
$26.5M
| $6.34M | 6.3% |
2,087,139
| – | – |
|
|
RNAM
8
DELISTED
Avidity Biosciences
RNAM
| $5.19M | 5.16% |
178,500
| – | – |
|
|
9
Ardelyx
ARDX
$976M
| $4.82M | 4.79% |
950,947
-120,000
| -11% | -$663K |
|
10
Abeona Therapeutics
ABEO
$343M
| $3.48M | 3.45% |
624,022
| – | – |
|
|
11
Syndax Pharmaceuticals
SNDX
$1.84B
| $2.42M | 2.41% |
183,259
+50,000
| +38% | +$856K |
|
12
Kymera Therapeutics
KYMR
$9.76B
| $2.27M | 2.25% |
56,359
| – | – |
|
13
Zevra Therapeutics
ZVRA
$736M
| $1.5M | 1.49% |
179,874
| – | – |
|
14
Kura Oncology
KURA
$1.18B
| $1.13M | 1.12% |
130,000
| – | – |
|
|
LONA
15
LeonaBio Inc
LONA
$71.2M
| $876K | 0.87% |
149,279
| – | – |
|
|
EIGR
16
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $765K | 0.76% |
146,381
| – | – |
|
|
17
Jasper Therapeutics
JSPR
$23.6M
| $428K | 0.42% |
+20,000
| New | +$416K |
|
|
18
Delcath Systems
DCTH
$572M
| $205K | 0.2% |
+17,000
| New | +$179K |
|
|
CMPS
19
Compass Pathways
CMPS
$1.84B
| $95.3K | 0.09% |
25,209
-54,791
| -68% | -$278K |
|
|
20
Telesat
TSAT
$683M
| – | – |
-365,781
| Closed | -$4.82M |
|
|
21
Verrica Pharmaceuticals
VRCA
$91M
| – | – |
-34,494
| Closed | -$500K |
|
Similar funds
CFG
MWM
ALWM
PFA
LKWM
NWM
AA
MCA
Propel Bio Management's Q4 2024 Portfolio in Review
As of Q4 2024, Propel Bio Management held 23 positions worth $101M, down 42% from $172M the previous quarter. Its ten largest holdings account for 90% of the portfolio.
Propel Bio Management deployed $15.8M of net new capital in Q4 2024, opening 2 new positions and adding to 4 existing holdings. Its largest new stake was Jasper Therapeutics: 20,000 shares worth $428K.
By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 84% a quarter earlier, followed by Energy and Miscellaneous.
On the sell side, the largest reduction was Ardelyx, an estimated $663K trimmed.
- Propel Bio Management's largest Q4 2024 buy was Jasper Therapeutics: 20,000 shares worth $428K.
- Propel Bio Management added most to Applied Therapeutics in Q4 2024, an estimated $19.1M increase.
- Propel Bio Management's biggest Q4 2024 reduction was Ardelyx, cutting an estimated $663K.
- Propel Bio Management fully exited Telesat in Q4 2024, selling an estimated $4.82M.
- Propel Bio Management's ten largest holdings make up 90% of its $101M portfolio in Q4 2024.
- Propel Bio Management opened 2 new positions and closed 2 in Q4 2024.
- Propel Bio Management's portfolio value fell 42% quarter-over-quarter to $101M.
Based on Propel Bio Management's 13F filing for Q4 2024, filed 14 Feb 2025.